Next, we studied the effect of ASGPR on liver accumulation of subcutaneously administered HF647-Lac-β-CyD, in the presence or absence of AF, a competitor for ASGPR (Figure 1b). The gene discussed is ASGR1; the disease is atrial fibrillation.